Anirban Maitra: Preclinical studies with a KRASG12V directed PROTAC
Anirban Maitra , Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared a post on X:
“A second KRASG12V degrader manuscript in ten days.
This one is published in Journal of Clinical Investigation and details preclinical studies with a KRASG12V directed PROTAC, using the dTAG-based pipeline from Behnam Nabet that enables degradation of specific proteins of interest in vivo by generating FKBP12F36V fusion proteins.
The preprint from 10 days prior also generated FKBP12F36V-KRASG12V mice with the dTAG pipeline for targeted protein degradation (TPD) in lung cancer.
Nice to see two independent efforts across the Atlantic come to fruition.”
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
Authors: Dezhi Li et al.
Dr. Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023